• 1.

    Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

  • 2.

    US Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). August 26, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

  • 4.

    Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:14131424. doi: 10.1056/NEJMoa2022190

  • 5.

    Zannad F, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced trial. Circulation 2021; 143:310321. doi: 10.1161/CIRCULATIONAHA.120.051685

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:22192229. doi: 10.1056/NEJMoa2025845

  • 7.

    Agarwal R, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:15401550. doi: 10.1016/S0140-6736(19)32135-X

    • PubMed
    • Search Google Scholar
    • Export Citation

SGLT2 Inhibitors Continue to Show Kidney, Heart Benefits at Kidney Week

Bridget M. Kuehn
Search for other papers by Bridget M. Kuehn in
Current site
Google Scholar
PubMed
Close
Restricted access
Save